For all of you who are currently taking Octreotide for carcinoid syndrome, by injection, there is some good news for you. The FDA has recently approved an oral form of this medication.

Here is a link to the article, "Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome"
https://www.globenewswire.com/news-release/2022/07/14/2479558/0/en/Amryt-Receives-Orphan-Drug-Designation-from-the-FDA-for-Mycapssa-oral-octreotide-for-the-Treatment-of-Carcinoid-Syndrome.html
Please note that Stage 3 trials of Mycapssa, to determine correct medication dosages, will begin sometime in 2023. We would not expect to see the drug become widely available until much later in 2023 and more likely early in 2024.